Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

A February 2026 paper published in the medical journal Pain Reports describes how a Canadian clinic specializing in pain management has validated a new pain measurement tool. The tool, named the Integral of Pain Relief (IPR), measures the changes in how a patient experiences pain over discrete time periods. It uses a simple mathematical formula […]

The post Integral of Pain Relief: A New Modality in Chronic Pain Measurement appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Are you unsatisfied with traditional primary care? You are not alone. According to one poll, most Americans are unhappy with their healthcare system. Through traditional healthcare models, patients are often left with long wait times, rushed appointments, less interaction with their primary care physician, and less-than-satisfactory quality of care. Concierge medicine offers an alternative to […]

The post Concierge Medicine vs. Traditional Primary Care: What’s the Difference? appeared first on Medical News Bulletin.

Only 10 human cases of Guinea worm disease were reported worldwide in 2025 — the lowest number ever recorded.
The Carter Center announced the historic data just after the 1-year anniversary of former President Jimmy Carter’s passing. The center, named for Carter and his wife Rosalynn, took over the global Guinea worm eradication effort in 1986, when there were approximately 3.5 million cases reported annually, primarily in Africa.
Guinea worm disease, also called dracunculiasis, is a parasitic disease transmitted through drinking water contaminated with Dracunculus medinensis. Approximately 1

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta; AbbVie, Genentech) received approval for adults with previously untreated CLL or small lymphocytic lymphoma.
The FDA based its decision on results from the randomized phase 3 AMPLIFY trial, which showed a 35% reduction in risk for disease progression or death with the combination, compared with chemoimmunotherapy.
“This FDA approval marks a

A single yes-or-no question could efficiently screen for low vision or legal blindness when a comprehensive exam is not cost-effective, according to a study published in Investigative Ophthalmology & Visual Science.
“In many settings, particularly in a remote study or large-scale public health studies, it is often impractical to perform comprehensive clinical VA assessments on every participant,” Yueh-Hsun Wu, PhD, assistant professor at The Ohio State University, and colleagues wrote. “Although self-reporting is cost-effective, its precision compared to gold-standard

ACOG announced updates to its clinical guidance on endometriosis, which include new comprehensive recommendations on diagnosis.
This guidance comes ahead of both Endometriosis Awareness Month in March and additional guidelines on endometriosis management that ACOG is developing, a press release said.
“Endometriosis pain can be incredibly burdensome for women and girls, and we know that on top of that pain, many patients experience understandable frustration due to delays in care and limited management options offered to them,” ACOG President Steven J. Fleischman, MD, MBA, FACOG, said in the

In 1996, a previously healthy 5-year-old girl presented to a local urgent care clinic with a 3-day history of fever and a progressive, generalized vesicular rash, diagnosed as varicella with a known exposure at her preschool.
Over the next 12 days, the fever and rash persisted, with the rash becoming hemorrhagic and involving the mucous membranes of the mouth and eyelids (Figures 1, 2 and 3). At the first visit, the family was told the skin lesions should crust over within a few days. She was not treated with an antiviral (acyclovir) since she presented more than 48 hours after the onset.

An 84-year-old man was referred to the oculoplastic service at Tufts Medical Center/New England Eye Center for evaluation of 3 months of binocular diplopia and right retroorbital pain. Outside imaging had revealed a right orbital mass.
The patient had a medical history of hypertension, hyperlipidemia, chronic obstructive pulmonary disease, Parkinson’s disease and depression. Surgical history was significant for spinal surgery for spina bifida at age 15 years. Ocular history was notable for cataract extraction and IOL implantation in both eyes. Social history revealed that he was a current

When I opened my laptop this morning, up popped a message on LinkedIn: Congratulations on 21 years at Allergan!
Stopped me in my tracks, to be honest. That is as long as my practice, SkyVision Centers, has been in existence. I have been an active consultant working with the teams at Allergan (now AbbVie) for 21 years. Reading that reminded me of how foundational the diagnosis and treatment of dry eye disease (DED) have been in the development of my career as both physician and physician-consultant. The arc of my career in many ways tracks the arc of DED treatment as a subspecialty.
It seems

Cataract surgery in the highly myopic patient, typically defined by an axial length greater than 26 mm, represents one of the most demanding scenarios in refractive cataract surgery.
While these patients often have the most to gain in terms of visual quality of life, they also carry a significantly higher risk profile for intraoperative complications and postoperative refractive surprises. As surgeons, our approach must be multifaceted, beginning with meticulous biometric analysis and extending to a lifetime of vitreoretinal vigilance.
The primary hurdle in high myopia is the refractive